Eli Lilly and Novo Nordisk launches lower-priced insulin options

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Eli Lilly and Novo Nordisk launches lower-priced insulin options

Biosimilars/General | Posted 24/01/2020 0 Post your comment

Originator insulin makers Eli Lilly and Novo Nordisk have both announced the introduction of additional reduced cost insulin options for patients.

Novo Nordisk announced on 2 January 2020 that it was launching its My$99Insulin Program, biosimilar versions of its insulin products and an ‘Immediate Supply’ option.

Via the My$99Insulin programme, patients can purchase up to three vials or two packs of FlexPen/FlexTouch/Penfill pens of any combination of insulins from Novo Nordisk for US$99. The Immediate Supply option, on the other hand, is a new, immediate, one-time insulin supply option available for people facing an acute need when more time is needed to identify a long-term sustainable solution.

Finally, the company also says that it is going to make authorized biosimilars (follow-on brand insulins) of NovoLog and NovoLog Mix (made by the new US company, Novo Nordisk Pharma) available at pharmacies within 1‒3 business days at 50% discount to the list price. The company first announced its plans to launch biosimilar versions of its NovoLog and NovoLog Mix insulin products in the US in October 2019 [1].

Eli Lilly announced on 14 January 2020 that it was expanding its insulin affordability options with lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen.

The company originally launched a lower-priced (50% lower than list price of originator) authorized biosimilar version [Insulin Lispro Injection (100 units/mL)] of its diabetes treatment Humalog (insulin lispro) in the US in May 2019 [2].

This new announcement now adds two further options for insulin users. The lower-priced versions will be known as Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (100 units/mL). Both insulins will also have a 50% lower list price compared to the brand-name version and will be available by mid-April 2020.

References
1. GaBI Online - Generics and Biosimilars Initiative. Novo Nordisk to launch biosimilar insulin in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jan 24]. Available from: www.gabionline.net/Biosimilars/General/Novo-Nordisk-to-launch-biosimilar-insulin-in-the-US
2. GaBI Online - Generics and Biosimilars Initiative. Eli Lilly launches lower-priced insulin lispro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jan 24]. Available from: www.gabionline.net/Biosimilars/General/Eli-Lilly-launches-lower-priced-insulin-lispro

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Eli Lilly, Novo Nordisk